A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
NCT05670925
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Primary location
Fudan University Shanghai Cancer Center Shanghai, China, 200032
A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. — TrialFind